Alexandra Cantley is a partner in Polaris Partners’ New York office, where she focuses on healthcare and biotech investments, and works closely with numerous Polaris portfolio companies including Podimetrics, Auron Therapeutics, Engine Biosciences and SunBird Bio. Prior to joining Polaris, Alexandra was part of the initial research team at Inzen Therapeutics, where she helped develop their platform technologies. She moved to Inzen from Vertex Pharmaceuticals, where she held a research fellowship. She received a PhD in Chemical Biology from Harvard University, where she studied natural product discovery and performed her undergraduate studies at New York University.
Board of Directors